Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Publications
3 shownActivity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Abstract Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of ...
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Recent progress in understanding the molecular basis of cancer has redefined the landscape for cancer drug discovery and development. Among the most exciting and promising benef...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 12,368
- Institution
- University of California, Los Angeles
External Links
Identifiers
- ORCID
- 0000-0002-6330-498X
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.